Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Rezvani, Katayoun  [Clear All Filters]
2024
Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, et al. Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2024.
Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, Alousi AM, Hosing C, Kebriaei P, Khouri I, et al. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024.
Marcoux C, Saliba RM, Wallis W, Khazal SJ, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, et al. Incidence and Risk Factors of Early Onset VOD/SOS Differ in Younger vs Older Adults After Stem Cell Transplantation. Blood Adv. 2024.
Febres-Aldana A, Khawaja F, Morado-Aramburo O, Shigle TLynn, Rondon G, Sassine J, Spallone A, Srinivasan K, Ramdial J, Alousi A, et al. Mortality in recipients of allogeneic hematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: A single center retrospective Experience. Clin Microbiol Infect. 2024.
Saliba RM, Lee SJ, Carpenter PA, Hill GR, Lee CJ, Alousi A, Daher M, Chen G, Champlin RE, Rezvani K, et al. Mycophenolate mofetil is associated with inferior overall survival in cytomegalovirus seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Haematologica. 2024.
Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, et al. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant. 2024.
Ciurea SO, Kongtim P, Srour S, Chen J, Soebbing D, Shpall E, Rezvani K, Nakkula R, Thakkar A, Troy EC, et al. Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML. Am J Hematol. 2024.
Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 B cell tumors: a phase 1/2 trial. Nat Med. 2024.
2023
Dragomir MP, Fuentes-Mattei E, Winkle M, Okubo K, Bayraktar R, Knutsen E, Qdaisat A, Chen M, Li Y, Shimizu M, et al. Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response. J Clin Invest. 2023.
Huang Y, Mohanty V, Dede M, Tsai K, Daher M, Li L, Rezvani K, Chen K. Characterizing cancer metabolism from bulk and single-cell RNA-seq data using METAFlux. Nat Commun. 2023;14(1):4883.
Saliba RM, Kanakry CG, Gadalla S, Kebriaei P, Rezvani K, Champlin RE, Shpall EJ, Weisdorf D, Mehta RS. Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol. 2023.
Nieto Y, Banerjee P, Kaur I, Kim KHee, Fang D, Thall PF, Griffin L, Barnett M, Basar R, Hosing C, et al. EX VIVO-EXPANDED CORD BLOOD NK CELLS COMBINED WITH RITUXIMAB AND HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS SCT FOR B-NHL. Transplant Cell Ther. 2023.
Ascierto PA, Brentjens R, Khleif SN, Odunsi K, Rezvani K, Ruella M, Sullivan RJ, Fox BA, Puzanov I. The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022. J Transl Med. 2023;21(1):275.
Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, et al. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv. 2023;9(30):eadd6997.
Zhang Y, Zhao Z, Huang LA, Liu Y, Yao J, Sun C, Li Y, Zhang Z, Ye Y, Yuan F, et al. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metab. 2023.
Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson AL, Chen J, Alousi AMajid, Al-Atrash G, Bashir Q, Gulbis AM, et al. Myeloablative Fractionated Busulfan for Allogeneic Stem Cell Transplant in Older Patients or Patients with Comorbidities. Blood Adv. 2023.
Li Y, Rezvani K, Rafei H. Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer. Immunol Rev. 2023.
Ascierto PA, Avallone A, Bifulco C, Bracarda S, Brody JD, Emens LA, Ferris RL, Formenti SC, Hamid O, Johnson DB, et al. Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022). J Transl Med. 2023;21(1):488.
Sanchez-Petitto G, Rezvani K, Daher M, Rafei H, Kebriaei P, Shpall EJ, Olson A. Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future. Stem Cells Transl Med. 2023.
2022
Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, et al. HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther. 2022.
Biederstädt A, Rezvani K. How I treat high-risk acute myeloid leukemia using pre-emptive adoptive cellular immunotherapy. Blood. 2022.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KHee, Kanagal-Shamanna R, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2022.
Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, et al. Post-Transplantation Cyclophosphamide vs Tacrolimus and Methotrexate Graft-versus-Host Disease Prophylaxis For HLA-Matched Donor Transplantation. Transplant Cell Ther. 2022.
2021
Biederstädt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. Int J Hematol. 2021.
Basar R, Uprety N, Ensley E, Daher M, Klein K, Martínez F, Aung F, Shanley M, Hu B, Gokdemir E, et al. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell Rep. 2021:109432.

Pages